CSIMarket
 
Advaxis Inc   (ADXS)
Other Ticker:  
 
 
Price: $0.9110 $0.05 5.807%
Day's High: $0.9689 Week Perf: 2.36 %
Day's Low: $ 0.91 30 Day Perf: 51.83 %
Volume (M): 1 52 Wk High: $ 1.95
Volume (M$): $ 1 52 Wk Avg: $0.99
Open: $0.97 52 Wk Low: $0.51



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Advaxis Inc
Ayala Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted cancer therapies. The company's goal is to improve the outcomes for patients with rare and aggressive cancers by leveraging precision medicine and advanced genomic profiling. Ayala Pharmaceuticals specializes in developing small molecule drugs that target specific genetic alterations found in cancer cells. Their lead product candidate, AL101, is being evaluated in clinical trials for the treatment of patients with advanced solid tumors and recurrent/metastatic adenoid cystic carcinoma (ACC). The company is committed to advancing its pipeline and bringing promising therapies to market, ultimately providing better treatment options for cancer patients.


   Company Address: 9 Deer Park Drive Monmouth Junction 8852 NJ
   Company Phone Number: 452-9813   Stock Exchange / Ticker: ADXS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Completing Patient Enrollments: A Milestone for Ayala Pharmaceuticals' Promising Desmoid Tumor Study

Published Tue, Feb 20 2024 1:15 PM UTC

Immunome Recognizes Completion of Patient Enrollment in Ayala Pharmaceuticals' Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsBOTHELL, Wash. - Immunome, Inc. recently acknowledged the announcement made by Ayala Pharmaceuticals, Inc. regarding the completion of patient enrollment in the Phase 3 RINGSIDE study. The study aims to evaluate the efficacy of AL102, a targ...

Product Service News

Immunome Acquires AL102 and AL101, Groundbreaking Drug Candidates for the Treatment of Desmoid Tumors, from Ayala Pharmaceuticals.

Published Tue, Feb 6 2024 1:00 PM UTC

Immunome Acquires AL102, a Promising Phase 3 Asset for the Treatment of Desmoid Tumors, from Ayala PharmaceuticalsIn a significant development in the field of targeted cancer therapies, Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on groundbreaking cancer treatments, has announced its acquisition of AL102 and the related drug candidate AL101 from Ayala Phar...

Advaxis Inc

Advaxis Inc's Astonishing -$1.82 Per Share Deficit Sends Shockwaves Through the Market in Recent Fiscal Period



In a year marked by economic uncertainties, Advaxis Inc, a prominent player in the Major Pharmaceutical Preparations sector, has demonstrated remarkable resilience. Despite posting a loss of $-1.82 per share in the most recent fiscal period, the company's financial performance has improved when compared to the previous year. Additionally, the company showcased its strength by experiencing a surge in revenue growth, albeit from a lower base. As we delve into the details, it becomes clear that Advaxis Inc is poised for a brighter future in the stock market.
Consistent Improvement in Earnings:
Advaxis Inc's performance in the latest fiscal period shows a positive trend. Compared to a loss of $-1.90 per share the previous year, the company successfully reduced its losses to $-1.82 per share. This improvement indicates that the company's management has been effective in addressing financial challenges and reducing expenses.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com